Unmasking CSF protein corona: Effect on targeting capacity of nanoparticles
10.1016/j.jconrel.2021.04.001 · doi-reference
Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes
10.1016/j.jconrel.2020.03.022 · doi-reference
100th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery
10.1021/acsmacrolett.0c00488 · doi-reference
Size-Dependent Regulation of Intracellular Trafficking of Polystyrene Nanoparticle-Based Drug-Delivery Systems
10.1021/acsami.7b05383 · doi-reference
Enhancing Tumor Penetration of Nanomedicines
10.1021/acs.biomac.7b00068 · doi-reference
Investigating the optimal size of anticancer nanomedicine
10.1073/pnas.1411499111 · doi-reference
MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition
10.1038/s41467-024-54854-2 · doi-reference
Synergistic Proteolysis Targeting Chimera Chemotherapy Conjugate for Potent Non-small Cell Lung Cancer Treatment
10.1021/acsami.5c18202 · doi-reference
Self-Assembled Molecular Glue Prodrug System for Enhanced Synergistic Tumor Therapy by Combining CDK12 Protein Degradation and Immunotherapy
10.1021/acsami.5c02939 · doi-reference
Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery
10.1016/j.addr.2026.115876 · doi-reference
Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon
10.1016/j.jconrel.2012.11.016 · doi-reference
A Decade of the Protein Corona
10.1021/acsnano.7b08008 · doi-reference
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles
10.2147/ijn.s36111 · doi-reference
Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell
10.3390/pharmaceutics12040371 · doi-reference
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
10.1073/pnas.1522080113 · doi-reference
Physical traits of cancer
10.1126/science.aaz0868 · doi-reference
Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment
10.1039/c1cs15233e · doi-reference
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
10.1016/j.jconrel.2016.06.040 · doi-reference
Guest Leakage from ZIF-8 Particles under Drug Delivery Conditions: Quantitative Characterization and Guest-Induced Framework Stabilization
10.1021/acs.jpcc.1c03876 · doi-reference
Mitigating metal-organic framework (MOF) toxicity for biomedical applications
10.1016/j.cej.2023.144400 · doi-reference
Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review
10.2147/ijn.s451919 · doi-reference
Synthesis of mesoporous silica nanoparticles
10.1039/c3cs35405a · doi-reference
Current status on the biodegradability of acrylic polymers: microorganisms, enzymes and metabolic pathways involved
10.1007/s00253-020-11073-1 · doi-reference
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
10.3390/pharmaceutics17040501 · doi-reference
PEG–PLGA copolymers: Their structure and structure-influenced drug delivery applications
10.1016/j.jconrel.2014.03.026 · doi-reference
Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
10.1021/acsnano.4c09800 · doi-reference
Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery
10.1016/j.biomaterials.2025.123621 · doi-reference
Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies
10.1021/acsnano.1c05922 · doi-reference
The Nanocarrier Landscape—Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective
10.1021/acsami.5c07366 · doi-reference
Factors governing tumor penetration of nanomedicines: intrinsic and extrinsic determinants
10.1039/d5nr04462f · doi-reference
In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
10.1002/anie.202421713 · doi-reference
DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases
10.1038/s41467-025-60039-2 · doi-reference
PROTAC Prodrug-Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer
10.1002/adma.202314132 · doi-reference
Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy
10.1021/acs.jmedchem.3c00587 · doi-reference
Light-Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy
10.1002/adma.202405475 · doi-reference
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
10.1038/s41467-024-50735-w · doi-reference
Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy
10.1002/adma.202208553 · doi-reference
Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor
10.1016/j.chembiol.2024.01.002 · doi-reference
Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma
10.1002/adma.202504253 · doi-reference
A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy
10.1007/s12274-024-6974-x · doi-reference
